Bird Flu March Color Epivax 2017

BARDA, WHO, CDC and H7N9: Doing the Same Thing All Over Again?

“Insanity: doing the same thing over and over again and expecting different results.” – Albert Einstein. Due to its high rate of lethality (30-40%) and pandemic potential, H7N9 preparedness has become a priority for public health officials. While mutations that would enable … Continue reading

Posted in Blog, Featured, News | Tagged , , , , , , , , , , , | Leave a comment
zuben-sauna-fvii-mutation-analysis-2017

Our Prediction for 2017: Out with Post Hoc and Go DeFT! 

It’s a new year and welcome to it! Pundits are making a lot of predictions about the decline of science and technology under the new administration in Washington DC, and I’m here with a contrarian view. We bet on biotechnology! We predict … Continue reading

Posted in Blog, Featured, News | Tagged , , , , , , | Leave a comment
immuno-screening-mab

Update: Screening for Immunogenicity: Immunotherapy Challenges and Predictive Approaches Applied to Therapeutic Proteins 

Update: This event has been cancelled by the organizers. Thank you for your interest. As an expert in immunogenicity screening, EpiVax’s CEO/CSO, Dr. Annie De Groot, will be conducting a training on state of the art methods of in silico and in … Continue reading

Posted in Events, Featured | Tagged , , , , , , , , , , , | Leave a comment
tularemia bacteria

$1.87M BioDefense Grant to EpiVax and CUBRC

CUBRC and EpiVax Awarded DTRA Grant worth $1.87 Million to Perform Research into Vaccine Antigen Design for Burkholderia pseudomallei Buffalo, NY – December 19, 2017 – CUBRC, Inc.’s President and CEO, Tom McMahon, announced today that CUBRC’s Biological and Medical … Continue reading

Posted in Featured, News | Tagged , , , , , , | Leave a comment
epivax-logo

The Ancer to Cancer: A computational pipeline for personalized cancer vaccine design

Building on 18 years of commercially successful research and development in the field of computational immunology, EpiVax has now developed Ancer™, a personalized cancer vaccine platform. Ancer is a high-speed, secure, cloud-based commercial platform for processing cancer/normal protein sets, identifying … Continue reading

Posted in Blog, EpiVax Immunoncology, Featured, News | Tagged , , , , , , , , , , , , | Leave a comment
bioeurope-spring

Bio-Europe Spring

EpiVax will be joining more than 1,400 companies from over 45 countries at Bio-Europe Spring, the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in Europe’s most innovative biopharma clusters. Partner with us to … Continue reading

Posted in Blog, Events, Featured, News | Tagged , , , , , , | Leave a comment
H7N9

EpiVax to Advance Development of Vaccine Against Stealth Flu Virus with New NIH-SBIR Funding

September 6, 2016 (Providence, RI) – EpiVax, Inc., “immune engineering” pioneer, has won a new $600,000 National Institutes of Health grant under the Small Business Innovation Research (SBIR) program to improve a vaccine for the problematic H7N9 avian influenza virus. The … Continue reading

Posted in Featured, News | Tagged , , , , , | Leave a comment
Tokyo_780x520px

Westin Tokyo Immunogenicity Seminar 2016 (Updated)

UPDATE: Here are commemorative photos from our event. Thank you to all the speakers and participants for making the 2016 seminar a success. See you next year!   —- The 7th annual Westin Tokyo Immunogenicity Seminar is set for October 17th, … Continue reading

Posted in Events, Featured | Leave a comment
VIE-Awards-LOGO-smaller

Biotech CEO of the Year

Standards of excellence. Models of advocacy. An unparalleled ability to succeed. These are characteristics of the vaccine industry’s top achievers. Last night at the 9th Vaccine Industry Excellence (ViE) Awards, winners were recognized for their outstanding contributions to the vaccine industry over the past 12-months. EpiVax’s … Continue reading

Posted in Blog, Featured, News | Tagged , , , , | Leave a comment
IQT Quarterly Vaccines on Demand White Paper 2016

New publication in IQT Quarterly

Our latest mini-publication on ‘vaccines on demand’ can be found here: IQT Quarterly Winter 2016 – EpiVax Continue reading

Posted in Featured, News, Uncategorized | Tagged , , , , , , | Leave a comment